{"organizations": [], "uuid": "0e69808adf664ab2d872702efffa6deafef31e34", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180515.html", "section_title": "Archive News &amp; Video for Tuesday, 15 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-helius-medical-if-co-fails-to-ensu/brief-helius-medical-if-co-fails-to-ensure-commercialization-of-pons-treatment-is-available-for-u-s-government-by-dec-31-2021-co-may-forfeit-right-to-pursue-commercialization-idUSFWN1SM0O4", "country": "US", "domain_rank": 408, "title": "BRIEF-Helius Medical - If Co Fails To Ensure Commercialization Of Pons Treatment Is Available For U.S. Government By Dec. 31, 2021, Co May Forfeit Right To Pursue Commercialization", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.034, "site_type": "news", "published": "2018-05-15T19:24:00.000+03:00", "replies_count": 0, "uuid": "0e69808adf664ab2d872702efffa6deafef31e34"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-helius-medical-if-co-fails-to-ensu/brief-helius-medical-if-co-fails-to-ensure-commercialization-of-pons-treatment-is-available-for-u-s-government-by-dec-31-2021-co-may-forfeit-right-to-pursue-commercialization-idUSFWN1SM0O4", "ord_in_thread": 0, "title": "BRIEF-Helius Medical - If Co Fails To Ensure Commercialization Of Pons Treatment Is Available For U.S. Government By Dec. 31, 2021, Co May Forfeit Right To Pursue Commercialization", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "helius medical technologies inc", "sentiment": "neutral"}, {"name": "reuters", "sentiment": "neutral"}, {"name": "brief-helius medical", "sentiment": "neutral"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "a&b", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 15 (Reuters) - Helius Medical Technologies Inc:\n* HELIUS MEDICAL TECHNOLOGIES - IF CO FAILS TO ENSURE COMMERCIALIZATION OF PONS TREATMENT IS AVAILABLE FOR U.S. GOVERNMENT BY DEC. 31, 2021, CO MAY FORFEIT RIGHT TO PURSUE COMMERCIALIZATION\n* HELIUS MEDICAL - IF CO FAILS TO OBTAIN FDA MARKETING AUTHORIZATION OF PONS DEVICE BY DEC 31, 2021 CO WILL BE IN BREACH OF CRADA IF TERMINATION DATE IS NOT EXTENDED\n* HELIUS MEDICAL- IF CO FAILS TO OBTAIN MARKETING AUTHORIZATION, ENSURE PONS DEVICE IS AVAILABLE FOR GOVERNMENT BY DEC. 31, 2021, CO MAY BE REQUIRED TO PAY $2 MILLION TO A&B\n* HELIUS MEDICAL- LOSS OF CO'S ABILITY TO EXCLUSIVELY MARKET AND SELL THE PONS TREATMENT WOULD HAVE A MATERIAL ADVERSE EFFECT ON ITS BUSINESS Source text: ( bit.ly/2jVt4ZU ) Further company coverage: (Reuters.Briefs@thomsonreuters.com)\nOur Standards: The Thomson Reuters Trust Principles. ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "https://bit.ly/2jVt4ZU", "https://instagram.com/reuters/"], "published": "2018-05-15T19:24:00.000+03:00", "crawled": "2018-05-16T19:09:40.000+03:00", "highlightTitle": ""}